Valneva Vaccine Portfolio and Development History
Valneva is a biotechnology company focused on the development and commercialization of vaccines to combat infectious diseases. By leveraging various platforms, the company has successfully brought several critical vaccines to global markets while navigating the complex landscape of clinical trials and regulatory approvals.
Marketed Vaccines
Valneva has established a presence in several international markets with a diverse range of approved vaccines. These products target specific regional and global health threats:
- Ixiaro: A vaccine designed to prevent Japanese encephalitis, approved for use in Australia, America, and Europe.
- Dukoral: A vaccine targeting cholera and enterotoxigenic Escherichia coli (LT-ETEC), approved in Australia, Canada, and Europe.
- IXCHIQ: A single-dose, live-attenuated vaccine developed to protect against the chikungunya virus.
COVID-19 Vaccine Development: VLA2001
In response to the global pandemic, Valneva partnered with Dynavax Technologies to create VLA2001, an inactivated whole virus vaccine. This candidate was derived from the technology used in the Ixiaro Japanese encephalitis vaccine.
Clinical Trials and UK Partnership
The development of VLA2001 involved a Phase 1/2 trial in the United Kingdom with 150 participants. This study tested three different dose levels to evaluate safety, tolerability, and immunogenicity (the ability of a vaccine to provoke an immune response). The trial was expected to conclude by February 15, 2021, with full reporting by August 2021.
Supported by the UK National Institute for Health Research and four British universities, Valneva adopted an accelerated development path. Rather than following a traditional sequential approach, the company progressed immediately into Phase 3 trials and expanded production capacity at its facility in Livingston, Scotland, while the Phase 1/2 evaluation was still ongoing.
Regulatory Approval and Market Challenges
The UK government initially pre-ordered 60 million doses, with a total potential agreement for up to 100 million doses. However, in September 2021, the UK government cancelled the order. While no official reason was provided, the cancellation appeared to be linked to Brexit-related difficulties in obtaining building materials rather than the quality of the vaccine.
Despite the order cancellation, the UK Medicines and Healthcare products Regulatory Agency (MHRA) granted approval to the vaccine on April 14, 2022, making it the first country in the world to do so. Shortly after, on May 17, 2022, the European Commission cancelled its advance purchase agreement, which would have seen the delivery of 60 million doses over two years.
[ไม่มีภาพประกอบ]Research, Development, and Clinical Failures
Vaccine development is a high-risk endeavor, and Valneva has experienced several setbacks in its therapeutic pipeline. Several candidates failed to meet their goals during clinical trials, including:
- VLA43: A therapeutic vaccine targeting Pseudomonas aeruginosa.
- V710: A therapeutic vaccine against Staphylococcus aureus, developed in collaboration with Merck.
- IC41: A therapeutic vaccine designed for hepatitis C.
Regarding future prospects, Valneva announced positive Phase 1 clinical trial results in November 2025. However, the company noted that the regulatory pathways and market opportunities for a potential Zika vaccine remain uncertain unless a major investor is secured, despite the existing medical need.
Key Facts
- Approved Products: Ixiaro (Japanese encephalitis), Dukoral (cholera/LT-ETEC), and IXCHIQ (chikungunya).
- VLA2001: An inactivated whole virus COVID-19 vaccine approved by the UK's MHRA in April 2022.
- Manufacturing: VLA2001 is produced at a facility in Livingston, Scotland.
- Trial Scale: The VLA2001 Phase 1/2 trial included 150 participants.
- R&D Challenges: Failed candidates include VLA43, V710, and IC41.
| Vaccine Name | Target Disease | Status/Approval Region |
|---|---|---|
| Ixiaro | Japanese encephalitis | Europe, America, Australia |
| Dukoral | Cholera and LT-ETEC | Europe, Canada, Australia |
| IXCHIQ | Chikungunya virus | Marketed (Single-dose) |
| VLA2001 | COVID-19 | Approved by UK MHRA |
Frequently Asked Questions
What is the purpose of the Ixiaro vaccine?
Ixiaro is a vaccine used to protect against Japanese encephalitis and is approved for use in America, Europe, and Australia.
Why did the UK government cancel its order for VLA2001?
While no official reason was given, the cancellation appeared to be related to difficulties in acquiring building materials due to Brexit, rather than issues with the vaccine's quality.
Which regulatory body was the first to approve Valneva's COVID-19 vaccine?
The UK Medicines and Healthcare products Regulatory Agency (MHRA) was the first in the world to approve the VLA2001 vaccine on April 14, 2022.
What happened to Valneva's therapeutic vaccine candidates?
Several candidates failed in clinical trials, specifically VLA43 (Pseudomonas aeruginosa), V710 (Staphylococcus aureus), and IC41 (hepatitis C).
What is the current status of the Zika vaccine development?
Despite positive Phase 1 results in November 2025, the company stated that market opportunities and regulatory pathways remain uncertain without a major investor.